Circa/Hi-Tech merger off
Circa Pharmaceuticals and Hi-Tech Pharmacal have ended merger discussions due to an inability "to mutually agree on certain terms and conditions relating to the intended merger," the firms announce May 5. Circa and Hi-Tech will continue to work together under a development and marketing agreement initiated in early 1993 involving ANDAs for products in the anti-inflammatory, antibiotic and anti-ulcer areas. The companies announced March 22 that Circa would be acquiring Hi-Tech in a $65 mil. stock swap ("The Pink Sheet" March 28, T&G-2)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth